Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab

被引：3
|
作者：
Naqash, Abdul R. [1 ]
Stroud, Geoffrey [1 ]
Collichio, Frances A. [2 ]
Muzaffar, Mahvish [1 ]
Sharma, Nitika [1 ]
Walker, Paul [1 ]
机构：
[1] East Carolina Univ, Div Hematol Oncol, 600 Moye Blvd, Greenville, NC 27858 USA
[2] Univ N Carolina, Div Hematol Oncol, Lineberger Comprehens Ctr, Chapel Hill, NC USA
来源：
ACTA ONCOLOGICA | 2017年 / 56卷 / 10期
关键词：
IPILIMUMAB; IMMUNOTHERAPY; COMBINATION;
D O I：
10.1080/0284186X.2017.1324212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1327 / 1330
页数：4
相关论文
共 50 条
  • [41] Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Nigel Fleeman
    Adrian Bagust
    Angela Boland
    Sophie Beale
    Marty Richardson
    Ashma Krishan
    Angela Stainthorpe
    Ahmed Abdulla
    Eleanor Kotas
    Lindsay Banks
    Miranda Payne
    PharmacoEconomics, 2017, 35 : 1035 - 1046
  • [42] Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Fleeman, Nigel
    Bagust, Adrian
    Boland, Angela
    Beale, Sophie
    Richardson, Marty
    Krishan, Ashma
    Stainthorpe, Angela
    Abdulla, Ahmed
    Kotas, Eleanor
    Banks, Lindsay
    Payne, Miranda
    PHARMACOECONOMICS, 2017, 35 (10) : 1035 - 1046
  • [43] The safety of nivolumab for the treatment of metastatic melanoma
    O'Reilly, Aine
    Larkin, James
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (08) : 955 - 961
  • [44] Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab
    Afzal, Muhammad Z.
    Shirai, Keisuke
    JOURNAL OF IMMUNOTHERAPY, 2019, 42 (04) : 136 - 141
  • [45] Combination of Talimogene laherparepvec (T-VEC) and Ipilimumab - complete Remission of a non-resectable, metastatic Melanoma
    Maul, L.
    Hauschild, A.
    Kahler, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 32 - 33
  • [46] Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response
    Iglesias, Pablo
    Ribero, Simone
    Barreiro, Alicia
    Podlipnik, Sebastian
    Carrera, Cristina
    Malvehy, Josep
    Puig, Susana
    ACTA DERMATO-VENEREOLOGICA, 2019, 99 (02) : 232 - 233
  • [47] Retrospective Analysis of Talimogene Laherparepvec (T-VEC) in Advanced Melanoma: Efficacy, Safety, and Patient Outcomes
    Rahimi, G.
    Garsa, A.
    Kokot, N.
    Hu, Chong J.
    Swanson, M.
    Butcher, K.
    Thomas, J.
    Lim, A.
    In, G.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2025, 73 (01) : 515 - 516
  • [48] Nivolumab exposure in a hemodialysis patient with metastatic melanoma
    Gulikers, Judith L.
    Croes, Sander
    Schreurs, Marco J. W.
    Litjens, Elisabeth J. R.
    Aarts, Maureen J. B.
    van Geel, Robin M. J. M.
    MELANOMA RESEARCH, 2021, 31 (06) : 579 - 581
  • [49] Talimogene Laherparepvec (T-VEC) for Patients with advanced Melanoma - complete Remission in a Patient with Organ Transplantation
    Ressler, J.
    Hoeller, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 58 - 59
  • [50] New Lymphadenopathy in a Patient with Metastatic Melanoma on Nivolumab
    Assadi, J.
    Chin, K. H.
    Sachdeva, A.
    Pickering, E.
    Holden, V. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
12345